

SECTION I

General Aspects of Vaccination

- 1 A Short History of Vaccination
- 2 Vaccine Immunology
- 3 Non-specific Effects of Vaccines
- 4 Correlates of Protection
- 5 The Vaccine Industry
- 6 Vaccine Manufacturing
- 7 Evolution of Adjuvants Across the Centuries
- 8 Vaccine Additives and Manufacturing Residuals in Vaccines Licensed in the United States
- 9 Passive Immunization

SECTION II

Licensed Vaccines and Vaccines in Development

- 10 General Immunization Practices
- 11 Human Adenovirus Vaccines
- 12 Anthrax Vaccines
- 13 Biodefense Vaccines, Vaccines for Emerging Infectious Diseases, and Coalition for Epidemic Preparedness Innovations (CEPI)
- 14 Cancer Vaccines
- 15 Cholera Vaccines
- 16 Combination Vaccines
- 17 Coronavirus Vaccines
- 18 Cytomegalovirus Vaccines
- 19 Dengue Vaccines
- 20 Vaccines Against Diarrhea Caused by Noncholera Bacteria
- 21 Diphtheria Toxoid
- 22 Ebola Vaccines
- 23 Nonpolio Enteroviruses
- 24 Epstein–Barr Virus Vaccines
- 25 Haemophilus Influenzae Type b Vaccines
- 26 Hepatitis A Vaccines
- 27 Hepatitis B Vaccines
- 28 Hepatitis C Vaccines
- 29 Hepatitis E Vaccines
- 30 Herpes Simplex Virus Vaccines
- 31 Human Immunodeficiency Virus Vaccines
- 32 Human Papillomavirus Vaccines
- 33 Inactivated and Recombinant Influenza Vaccines
- 34 Influenza Vaccine—Live
- 35 Japanese Encephalitis Vaccines
- 36 Lyme Disease Vaccines—the Journey Continues
- 37 Malaria Vaccines
- 38 Measles Vaccines
- 39 Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines
- 40 Meningococcal Vaccines Directed at Capsular Group B
- 41 Mumps Vaccines
- 42 Noninfectious Disease Vaccines
- 43 Norovirus
- 44 Parasitic Disease Vaccines
- 45 Pertussis Vaccines
- 46 Plague Vaccines
- 47 Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines
- 48 Pneumococcal Polysaccharide Vaccines
- 49 Poliovirus Vaccine—Inactivated
- 50 Poliovirus Vaccine—Live
- 51 Lyssaviruses and Rabies Vaccines
- 52 Respiratory Syncytial Virus Vaccines and Monoclonal Antibodies
- 53 Rotavirus Vaccines
- 54 Rubella Vaccines
- 55 Smallpox and Vaccinia
- 56 Staphylococcus aureus Vaccines
- 57 Streptococcus Group A Vaccines
- 58 Streptococcus Group B Vaccines
- 59 Tetanus Toxoid
- 60 Tickborne Encephalitis Vaccines
- 61 Tuberculosis Vaccines
- 62 Typhoid Fever Vaccines
- 63 Varicella Vaccines
- 64 Yellow Fever Vaccine
- 65 Zika Virus Vaccines
- 66 Zoster Vaccines

SECTION III

New Technologies

67 Technologies for Making New Vaccines

68 Genetic-Based Vaccine Vectors

69 Technologies to Improve Immunization

SECTION IV

Vaccination of Special Groups

70 Vaccination of Immunocompromised Hosts

71 Vaccines for International Travel

72 Vaccines for Healthcare Personnel

73 Vaccination of Pregnant Women

SECTION V

Public Health and Regulatory Issues

74 Immunization in the United States

75 Immunization in Europe

76 Immunization and Vaccine-Preventable Diseases in the Asia-Pacific Region

77 Immunization in Low- and Middle-Income Countries

78 Community Protection

79 Economic Analyses of Vaccine Policies

80 Regulation and Testing of Vaccines in the US

81 Regulation of Vaccines in Europe

82 Regulation of Vaccines in Low- and Middle-Income Countries

83 Vaccine Safety

84 Vaccine Hesitancy and Behavioral Factors Associated With Vaccine Uptake

85 Legal Issues

86 Ethics

ONLINE ONLY

87 Vaccines to Prevent Mpox

APPENDIX

Websites and Applications for Mobile Devices With Information About Immunization

Index